Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective

K Cooper, J O'D McGee

Cervical cancer is the second most common cancer globally. Four out of every five new cases of cervical cancer are diagnosed in developing countries worldwide. There is now sufficient evidence to suggest that the risk of developing cervical cancer is sexually transmitted. Epidemiological and experimental evidence suggests that human papillomavirus (HPV) is the infectious agent associated with cervical cancer. A recent survey of over 1000 specimens of cervical cancer from 22 countries confirmed conclusively that genital HPV is the main aetiologic factor in cervical cancer worldwide. This study also demonstrated that more than 20 different genital HPV types are associated with cervical cancer from several countries.

A large study screening biopsy specimens from low/high grade squamous intraepithelial lesions and cervical cancers grouped different genital HPV types according to their prevalence. These groups were as follows: HPV 6, 11, 42, 43, and 44 as low risk types; HPV 31, 33, 35, 51, 52, and 58 as intermediate risk types; and HPV 16, 18, 45, and 56 as high risk types. In the USA the prevalence of HPV DNA in definite cases of cervical intraepithelial neoplasia (CIN) approaches 100%, with high risk HPV types accounting for over 50% of infections. The results of Koutsy et al. support a direct progression of HPV infection to high grade CIN. These authors observed a high risk of rapid progression of HPV 16 or 18 cervical infection (cytologically negative) to high grade CIN in a cohort study. An independent cohort study from Finland arrived at similar conclusions, albeit over a longer period of time. A UK study examining a cohort of untreated patients with epithelial abnormalities of the cervix showed that detection of HPV 16 or 18 DNA sequences was associated with a significantly increased risk of disease progression. Hence, the type of HPV found in the cervix seems to predict the risk of progression to high grade cervical neoplasia. This association has been verified in both cross-sectional and prospective studies.

Recently, the role of HPV type specific persistent infection, especially in patients with a continual high viral load, has been associated with persistent cervical dysplasia. This prospective study focused on the determinants of persistence and progression versus regression of CIN in women with lesions diagnosed as CIN grade II. Repeated examinations over 15 months demonstrated persistent high levels of HPV detection (positive repeatedly by Southern blot) to be most predictive of CIN.

In Sweden the examination of archival Pap smears taken prior to the diagnosis of HPV-containing cervical carcinoma has detected HPV DNA in the majority of smears preceding the cancer. Where preceding multiple smears were available, persistent HPV infection was demonstrated over a seven year period preceding the cancer diagnosis. A similar study from the Netherlands, assessing false negative archival Pap smears performed up to six years preceding the diagnosis of cervical cancer, demonstrated persistent HPV 16 or 18 in the majority of archival smears. These studies demonstrate that persistent HPV infection with a high risk type is strongly associated with cervical dysplasia and carries a greater risk of subsequent progression to cervical cancer. Furthermore, these studies indicate that the inclusion of HPV testing with cytological screening may help reduce the number of false negative smears. The mechanisms by which persistence of viral DNA within keratinocytes contributes to the process of cell transformation include viral integration and extrachromosomal viral DNA replication. The latter involves a relation between viral gene expression, viral replication and cellular DNA replication pathways. In addition, if a high viral load does prove to be predictive of persistent cervical epithelial abnormalities, then the use of Hybrid Capture for HPV detection may be a useful system to quantify the amount of HPV DNA present in a sample.

It is widely accepted that HPV infection alone is not responsible for cervical neoplasia and that several co-factors have been identified. Although smoking, hormones and immune status are key co-factors in cervical carcinogenesis, none has been shown to predict the risk of progression to high grade cervical neoplasia. There is increasing evidence that the physical state of HPV within the nucleus of the host cell may play a major role in predicting the risk of progression of CIN. In fact, a pattern
has emerged regarding the physical state of HPV DNA in CIN and squamous cell carcinoma (SCC) of the cervix.16—episomally predominant in the early stages of CIN with integrated virus being detected more frequently in HPV positive, high grade CIN and SCC. The latter may or may not contain episomes as well. It has also been proposed that the physical state of HPV DNA may reflect a progression towards the malignant phenotype,20 21 and that higher grade CIN lesions may originate from a single cell clone in which viral integration had occurred.20 22 23 Hence, apart from CIN grade and HPV type being established risk factors in clinical progression,24 25 there is strong evidence that the physical state of HPV DNA is also relevant.

These observations are strongly supported by in vitro experimental evidence regarding the interactions between viral transforming oncoproteins and host cell tumour suppressor gene products—p53 and Rb.26,27 Tumour suppressor genes are responsible for the regulation of normal cell growth, and hence the demonstrated in vitro binding of their proteins with viral oncoproteins E6 and E7 has been proposed to result in loss of functional regulation of the cell growth control of the host cell.28 Hence the brakes on cell growth control are removed, resulting in dysregulation of the cell cycle. The importance of E6/p53 and E7/Rb binding is substantiated further as their ability to bind cell proteins is related to the oncogenicity of the HPV type. For example, E6/E7 oncoproteins from HPV 16/18 bind p53/Rb (respectively) more strongly than HPV 6/11 viral oncoproteins.26

It thus becomes increasingly apparent that the detection of integrated viral particles in human cervical epithelium may be important in clinical management of HPV associated cervical neoplasia. This was recently demonstrated in a study estimating the four-year disease-free survival of women with stage Ib cervical cancer.29 It was found that detection of integrated HPV DNA in the primary tumour was strongly associated with treatment failure. This is the first study highlighting the role of viral integration as a prognostic marker in early cervical cancer. Furthermore, HPV detection and integrated state was not associated with any other clinical variable—for example, histopathology, age at diagnosis, type of treatment, or size of lesion. These authors30 used a previously described non-isotopic in situ hybridisation (NISH) assay31 to determine the integrated state of HPV in cervical cancer tissue. The correlation of NISH pattern (punctate/dot/type 2 signal) with HPV integration as determined by Southern blot hybridisation and two-dimensional gel electrophoresis has been verified previously.32 This NISH assay is applicable to archival tissue33 and firmly establishes the location of integrated HPV DNA sequences within tumour cells. This overcomes the technical problems of DNA fragmentation (with inadequate DNA extraction), presence of inhibitors and contamination associated with PCR analysis which has been used to determine the physical state of HPV.34 The NISH assay is also a molecular technique that can be completed within a single working day, permitting easy access to the diagnostic histopathologist for clinical application.

The NISH assay is also capable of distinguishing integrated from episomal viral sequences on morphological grounds. Hence, type 1 (diffuse) represents episomal HPV, type 2 (dot) integrated HPV, and type 3 (mixed) a combination of episomal and integrated HPV.35 Following the description of the single dot and multidot nuclear signal patterns in cervical cancer,33 it was further proposed that these be designated 2a and 2b, respectively.35 These single dot signals may be subtle and indistinct,35 raising the need for extreme caution in the interpretation of NISH signal patterns. Such a cautious approach refers not only to false negativity, where subtle signals may be overlooked by the inexperienced observer, but also to false positivity. The need for a clean background both within the nucleus and on the slide cannot be overemphasised to prevent technical artefact from being misinterpreted as a positive signal.36 The converse is also true for the type 1/diffuse intranuclear signal where a subtle hint of "blush" may also be missed.35

A further problem is that occasional tumours may demonstrate HPV DNA NISH type 2/dot signals in an isolated focal single cell distribution.18 The significance of this pattern has not been elucidated in cervical carcinogenesis, but it is nevertheless plausible to assume that such a detection threshold may well be below that of Southern blot analysis of viral copies/cell. A highly specific and sensitive in situ hybridisation system has been shown to detect 10 viral copies/cell.37 In addition, these single type 2/dot signals indicating integrated virus, may also coexist with diffuse staining, varying copy number, episomal virus in cervical cancers.19 20 21 33 "This therefore raises interesting questions about the sensitivity of Southern analysis in the determination of the physical state of HPV, as viral—host chromosome junction fragments essential for determining isolated integrated virus in a tumour may be masked by a greater viral copy number of episomal virus.35

In summary, the role of NISH in the determination of the physical state of HPV in cervical preneoplastic/neoplastic lesions has now been confirmed by three independent laboratories using all available molecular investigative techniques.9 23 34 Furthermore, the use of the NISH assay in predicting the prognosis of early cervical cancers has been
Human papillomavirus, integration and cervical carcinogenesis

clearly demonstrated. Studies establishing the role of the NISH assay in predicting the progression of CIN to cervical cancer is awaited. The combined preservation of morphology with the physical state of HPV DNA in cervical cancers permits researchers access to a powerful investigative technique to pursue research into cervical carcinogenesis.


Molecular Pathology: what’s in a name?

This issue takes us into our third year. Our change of name is not merely cosmetic; our Editorial Board were in accord that the aims and content of the journal should be represented better by the exclusion of the word “clinical” from our title. This does not mean that we do not want to publish material with a clinical emphasis. Our ethos has always been to supplement the content of the Journal of Clinical Pathology with papers and reviews that include pure scientific work which furthers our understanding of disease mechanisms. Molecular Pathology is, therefore, a title which represents accurately the aims and content of this journal.

After only two volumes, Molecular Pathology has over 2000 institutional subscribers worldwide and a combined (with Journal of Clinical Pathology) impact factor of 1.607. Molecular Pathology is indexed in Index Medicus and Current Contents. This is very creditable for so young a publication and indicates that Molecular Pathology is being read and cited by many of our co-workers. We hope that you will continue to support and enjoy Molecular Pathology in the years to come.

With all good wishes for 1997.

John Crocker and David Burnett
Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective.
K Cooper and J O McGee

_Mol Path_ 1997 50: 1-3
doi: 10.1136/mp.50.1.1

Updated information and services can be found at:
http://mp.bmj.com/content/50/1/1.citation

Email alerting service

_These include:_
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/